摘要 |
Crystalline forms of 11-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridine-3-carboxamide. 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridine-3-carboxamide is useful in treating a disorder or a disease in a subject mediated by complement activation, in particular mediated by activation of the complement alternative pathway. |
申请人 |
NOVARTIS AG;TOWLER, CHRISTOPHER;ALTMANN, EVA;HOMMEL, ULRICH;LORTHIOIS, EDWIGE LILIANE JEANNE;MAIBAUM, JUERGEN KLAUS;OSTERMANN, NILS;QUANCARD, JEAN;RANDL, STEFAN ANDREAS;SIMIC, OLIVER;VULPETTI, ANNA |
发明人 |
TOWLER, CHRISTOPHER;ALTMANN, EVA;HOMMEL, ULRICH;LORTHIOIS, EDWIGE LILIANE JEANNE;MAIBAUM, JUERGEN KLAUS;OSTERMANN, NILS;QUANCARD, JEAN;RANDL, STEFAN ANDREAS;SIMIC, OLIVER;VULPETTI, ANNA;ROGEL, OLIVIER |